Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data

被引：0
|
作者：
Hamedi, Zahra
Lo, Andrea Yachee
Berkman, Jonathan David
Alesi, Erin R.
机构：
[1] Virginia Commonwealth Univ Hlth Syst, Div Hematol Oncol & Palliat Care, Massey Comprehens Canc Ctr, Richmond, VA USA
[2] Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6022
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tanaka, Hideki
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Tanaka, Nobukazu
    Takeshita, Naohiro
    Onaga, Ryutaro
    Hoshi, Yuta
    Wada, Akihisa
    Sato, Masanobu
    Ueda, Yuri
    Tahara, Makoto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Real-World Time on Treatment Analysis of Pembrolizumab Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Stratified by ECOG PS in the United States
    Black, C.
    Wang, L.
    Ramakrishnan, K.
    Turzhitsky, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E342 - E342
  • [33] Managing recurrent/metastatic head and neck cancer in the real-world: Paclitaxel plus Cetuximab
    Leao, I.
    Neto, R.
    Marinho, J.
    Neto, E.
    Dias, E.
    Joaquim, A.
    RADIOTHERAPY AND ONCOLOGY, 2019, 132 : 51 - 51
  • [34] Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
    Macia-Rivas, Lola
    Fernandez-Laguna, Clara luz
    Alvarez-Asteinza, Cristina
    Maray, Ivan
    Carbajales-Alvarez, Monica
    Lozano-Blazquez, Ana
    ANTICANCER RESEARCH, 2023, 43 (04) : 1681 - 1688
  • [35] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Bernier, Jacques
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 705 - 713
  • [36] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Jacques Bernier
    Nature Clinical Practice Oncology, 2008, 5 : 705 - 713
  • [37] Real-world data for immune checkpoint inhibitor therapy as first line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Wagner, S. M.
    Magnes, T.
    Minichsdorfer, C.
    Gamerith, G.
    Pall, G.
    Greil, R.
    Melchardt, T.
    Fuereder, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 132 - 133
  • [38] Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy
    Mehra, Ranee
    Huang, Huan
    Seal, Brian
    Tse, Jenny
    Shenolikar, Rahul A.
    Burudpakdee, Chakkarin
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (08): : 2030 - 2038
  • [39] Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck
    van der Linden, N.
    van Gils, C. W. M.
    Pescott, C. P.
    Buter, J.
    Vergeer, M. R.
    Uyl-de Groot, C. A.
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (08) : 2007 - 2016
  • [40] Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck
    N. van der Linden
    C. W. M. van Gils
    C. P. Pescott
    J. Buter
    M. R. Vergeer
    C. A. Uyl-de Groot
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 2007 - 2016
12345